Agios Pharmaceuticals | AGIO - Assets


Agios Pharmaceuticals reported $1.06B in Assets for its fiscal quarter ending in September of 2026.





Assets Change Date
AbbVie USD 147.68B 12.57B Sep/2026
Agios Pharmaceuticals USD 1.06B 44.38M Sep/2026
Alnylam Pharmaceuticals USD 7.99B 2.44B Sep/2026
Amgen USD 96.05B 409M Sep/2026
Arrowhead Research USD 1.74B 373.76M Sep/2026
Astellas Pharma JPY 3.53T 164.74B Sep/2026
AstraZeneca USD 119.92B 4.09B Sep/2026
Bayer EUR 113.47B 6.18B Sep/2026
Biogen USD 32.05B 32.5M Sep/2026
BioMarin Pharmaceutical USD 11.57B 154.21M Sep/2026
Bristol-Myers Squibb USD 88.77B 1.14B Sep/2026
Daiichi Sankyo JPY 4.26T 144.08B Sep/2026
Eli Lilly USD 148.07B 5.79B Sep/2026
Exelixis USD 2.51B 19.26M Sep/2026
Gilead Sciences USD 51.41B 2.05B Sep/2026
GlaxoSmithKline GBP 71.7B 9.96B Sep/2026
Incyte USD 7.29B 585.39M Sep/2026
Ionis Pharmaceuticals USD 2.91B 81.91M Sep/2026
Merck USD 132.77B 2.97B Sep/2026
Moderna USD 13.47B 2.51B Sep/2026
Nektar Therapeutics USD 763.27M 482.86M Mar/2026
Novartis USD 117.15B 4.88B Sep/2026
Novartis USD 117.15B 1.38B Sep/2026
Pfizer USD 204.54B 3.41B Sep/2026
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Regeneron Pharmaceuticals USD 44.41B 2.67B Sep/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
Sarepta Therapeutics USD 3.17B 22.45M Sep/2026
Vertex Pharmaceuticals USD 32.74B 5.31B Sep/2026